# Kyntra Bio, Inc.: overview KYNB · Nasdaq · CIK 921299 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/kynb.md) · [Financials](/companies/kynb/financials.md) · [Filings](/companies/kynb/filings.md) · [Insiders](/companies/kynb/insiders.md) Latest reported revenue: [−$1.5m](/filings/0001193125-26-349183.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-349183). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.1](/filings/0001193125-25-274241.md) | [3.1 d](/filings/0001193125-26-108346.md) | [2.7](/filings/0001193125-26-219374.md) | [1.3](/filings/0001193125-26-349183.md) | [1.1](/filings/0001193125-25-274241.md) | [1.3 d](/filings/0001193125-26-108346.md) | [3.7](/filings/0001193125-26-219374.md) | [(1.5)](/filings/0001193125-26-349183.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(38774.0%)](/filings/0001193125-25-274241.md) | [(227.5%) d](/filings/0001193125-26-108346.md) | [(544.7%)](/filings/0001193125-26-219374.md) | [(894.1%)](/filings/0001193125-26-349183.md) | [(502.9%)](/filings/0001193125-25-274241.md) | [(1058.1%) d](/filings/0001193125-26-108346.md) | [(369.7%)](/filings/0001193125-26-219374.md) | [1192.3%](/filings/0001193125-26-349183.md) | | Net margin | % | [(13889.4%)](/filings/0001193125-25-274241.md) | [573.6% d](/filings/0001193125-26-108346.md) | [169.4%](/filings/0001193125-26-219374.md) | [(564.0%)](/filings/0001193125-26-349183.md) | [18646.5%](/filings/0001193125-25-274241.md) | [(1113.5%) d](/filings/0001193125-26-108346.md) | [(406.6%)](/filings/0001193125-26-219374.md) | [(812.3%)](/filings/0001193125-26-349183.md) | | Diluted EPS | $ per share | [(4.25)](/filings/0001193125-25-274241.md) | not reported | [1.15](/filings/0001193125-26-219374.md) | [(1.88)](/filings/0001193125-26-349183.md) | [49.61](/filings/0001193125-25-274241.md) | not reported | [(3.76)](/filings/0001193125-26-219374.md) | [2.96](/filings/0001193125-26-349183.md) | | Free cash flow | $m | [(8.5) d](/filings/0001193125-25-274241.md) | [(30.6) d](/filings/0001193125-26-108346.md) | [2.7](/filings/0001193125-26-219374.md) | [12.7 d](/filings/0001193125-26-349183.md) | [(1.9) d](/filings/0001193125-25-274241.md) | [(18.3) d](/filings/0001193125-26-108346.md) | [(13.9)](/filings/0001193125-26-219374.md) | [(4.0) d](/filings/0001193125-26-349183.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [235](/filings/0000950170-24-020161.md) | [141](/filings/0000950170-24-020161.md) | [46.8](/filings/0000950170-25-040280.md) | [29.6](/filings/0001193125-26-108346.md) | [6.4](/filings/0001193125-26-108346.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(122.6%)](/filings/0000950170-24-020161.md) | [(213.9%)](/filings/0000950170-24-020161.md) | [(689.5%)](/filings/0000950170-25-040280.md) | [(507.8%)](/filings/0001193125-26-108346.md) | [(712.7%)](/filings/0001193125-26-108346.md) | | Net margin | % | [(123.3%)](/filings/0000950170-24-020161.md) | [(208.7%)](/filings/0000950170-24-020161.md) | [(607.3%)](/filings/0000950170-25-040280.md) | [(160.6%)](/filings/0001193125-26-108346.md) | [2848.6%](/filings/0001193125-26-108346.md) | | Diluted EPS | $ per share | [(3.14)](/filings/0000950170-24-020161.md) | [(3.14)](/filings/0000950170-24-020161.md) | [(2.92)](/filings/0000950170-25-040280.md) | [(11.89)](/filings/0001193125-26-108346.md) | [45.37](/filings/0001193125-26-108346.md) | | Free cash flow | $m | [(87.4)](/filings/0000950170-24-020161.md) | [(150)](/filings/0000950170-24-020161.md) | [(318)](/filings/0000950170-25-040280.md) | [(138)](/filings/0001193125-26-108346.md) | [(4.8)](/filings/0001193125-26-108346.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/kynb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $3.0m | 400,000 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.2m | 159,950 | | Added +3,343 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $675.0k | 89,400 | Call | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $636.7k | 84,330 | | Reduced −1 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $326.4k | 43,219 | | Reduced −2,779 | | [HighTower Advisors, LLC](/funds/1462245.md) | 2026-06-30 | $300.1k | 39,746 | | Added +2 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $298.3k | 39,511 | | Reduced −10,000 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $204.5k | 27,081 | | Reduced −400 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $182.0k | 24,105 | | Added +163 | | [Birchview Capital, LP](/funds/1618205.md) | 2026-06-30 | $170.4k | 22,566 | | Unchanged | ## Recent filings [All 1,175 filings](/companies/kynb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-06 | 20:05 ET | [8-K](/filings/0001193125-26-415545.md) | 3.01 Delisting notice | 0001193125-26-415545 | | 2026-10-01 | 11:30 ET | [8-K](/filings/0001193125-26-409819.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-409819 | | 2026-08-31 | 21:18 ET | [8-K](/filings/0001193125-26-377059.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-377059 | | 2026-08-13 | 20:10 ET | [10-Q](/filings/0001193125-26-349183.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349183 | | 2026-08-13 | 20:05 ET | [8-K](/filings/0001193125-26-349141.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349141 | | 2026-06-16 | 23:23 ET | [8-K](/filings/0001193125-26-271449.md) | 5.07 Shareholder vote results | 0001193125-26-271449 | | 2026-06-09 | 21:04 ET | [8-K](/filings/0001193125-26-264000.md) | 8.01 Other events | 0001193125-26-264000 | | 2026-05-12 | 20:05 ET | [10-Q](/filings/0001193125-26-219374.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219374 | | 2026-05-11 | 20:05 ET | [8-K](/filings/0001193125-26-216731.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-216731 | | 2026-04-27 | 20:06 ET | [DEF 14A](/filings/0001193125-26-182044.md) | Proxy statement, period 2026-06-12 | 0001193125-26-182044 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-108346.md), filed Mar 16, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/7444b186-a852-4e37-b296-c421d32ea53e) ## About the filer - CIK: 921299 - Tickers: KYNB - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.